The value of multiparameter 18F-FDG PET/CT imaging in differentiating retroperitoneal paragangliomas from unicentric Castleman disease

[1]  A. Sohani,et al.  Diagnosis and management of Castleman disease. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[2]  Y. Guan,et al.  The Diagnostic Value Of Using 18F-Fluorodeoxyglucose Positron Emission Tomography To Differentiate Between Low- And High-Grade Meningioma , 2019, Cancer management and research.

[3]  Lin Li,et al.  Castleman's disease. Large retroperitoneal masses and multiple calcifications detected by 18F-FDG PET/CT. , 2019, Hellenic journal of nuclear medicine.

[4]  M. García-Cosío,et al.  Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital , 2019, Leukemia & lymphoma.

[5]  É. Oksenhendler,et al.  Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases , 2019, British journal of haematology.

[6]  Xue-juan Wang,et al.  The correlation between molecular pathological profiles and metabolic parameters of 18F-FDG PET/CT in patients with gastroesophageal junction cancer , 2019, Abdominal Radiology.

[7]  J. Chen,et al.  Detection of a unicentric type of Castleman-like mass at the site of adrenal grand: A case report and review of literature , 2018, World journal of clinical cases.

[8]  S. Woo,et al.  Performance of 68Ga-DOTA–Conjugated Somatostatin Receptor–Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis , 2018, The Journal of Nuclear Medicine.

[9]  D. Ozdemir,et al.  18 F-FDG PET/CT findings in a patient with paraganglioma: Brown adipose tissue activation due to adrenergic stimulation , 2018, Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).

[10]  Q. Pan,et al.  Unicentric Castleman's Disease Revealed by 18F-FDG PET/CT and Somatostatin Receptor Scintigraphy With 99mTc-HYNIC-TOC. , 2018, Clinical nuclear medicine.

[11]  K. Herrmann,et al.  (18F)-FDG-PET/MRI of unicentric retroperitoneal Castleman disease in a pediatric patient. , 2018, Clinical imaging.

[12]  Xueqi Chen,et al.  Paraneoplastic Pemphigus Associated With Castleman Disease Detected by 18F-FDG PET/CT. , 2018, Clinical nuclear medicine.

[13]  F. Bertagna,et al.  18F-FDG PET/CT in splenic marginal zone lymphoma , 2018, Abdominal Radiology.

[14]  Kun Zhang,et al.  MR imaging features of benign retroperitoneal paragangliomas and schwannomas , 2018, BMC Neurology.

[15]  D. Özdemir,et al.  18F-FDG PET/CT findings in a patient with paraganglioma: Brown adipose tissue activation due to adrenergic stimulation. , 2018, Revista espanola de medicina nuclear e imagen molecular.

[16]  N. Shah,et al.  Genetic status determines 18F‐FDG uptake in pheochromocytoma/paraganglioma , 2017, Journal of medical imaging and radiation oncology.

[17]  M. Marzola,et al.  18F-FDG PET/CT of Brown Adipose Tissue Hyperactivation Associated With Pregnancy and Paraganglioma. , 2017, Clinical nuclear medicine.

[18]  T. Iwasaki,et al.  [A Resected Case of Castleman's Disease That Was Difficult to Diagnose Preoperatively]. , 2017, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  P. Ruszniewski,et al.  18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation , 2017, Neuroendocrinology.

[20]  L. Wuyts,et al.  Palpitations, headache and night sweats caused by a retroperitoneal mass: case report and short review , 2017, BJR case reports.

[21]  D. Tobin,et al.  Demographic Characteristics and Association of Serum Vitamin B12, Ferritin and Thyroid Function with Premature Canities in Indian Patients from an Urban Skin Clinic of North India: A Retrospective Analysis of 71 Cases , 2017, Indian journal of dermatology.

[22]  F. Bertagna,et al.  18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation , 2017, Leukemia & lymphoma.

[23]  M. Picchio,et al.  18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  J. Galvin,et al.  Castleman Disease of the Thorax: Clinical, Radiologic, and Pathologic Correlation: From the Radiologic Pathology Archives. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.

[25]  N. Patronas,et al.  Combined PET/CT by 18F-FDOPA, 18F-FDA, 18F-FDG, and MRI correlation on a patient with Carney triad. , 2015, Clinical nuclear medicine.

[26]  A. Sohani,et al.  Diagnosis and management of Castleman disease. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[27]  E. Fishman,et al.  The great mimickers: Castleman disease. , 2014, Seminars in ultrasound, CT, and MR.

[28]  M. Lin,et al.  FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index. , 2013, Clinical imaging.

[29]  C. Park,et al.  Metabolic Characteristics of Castleman Disease on 18F-FDG PET in Relation to Clinical Implication , 2013, Clinical nuclear medicine.

[30]  S. Kurata,et al.  High (18)F-FDG uptake in sporadic paraganglioma of the retroperitoneum may be related to intra-tumor haemorrhage and macrophages. , 2012, Hellenic journal of nuclear medicine.

[31]  A. Tischler,et al.  Warburg Effect’s Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue , 2012, PloS one.

[32]  Carlos Cuevas,et al.  Imaging of uncommon retroperitoneal masses. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[33]  E. Corssmit,et al.  Value of 123I-MIBG Scintigraphy in Paraganglioma , 2009, Neuroendocrinology.

[34]  A. Barlier,et al.  18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? , 2009, Journal of Nuclear Medicine.

[35]  H. Zhuang,et al.  99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma , 2009, Journal of Nuclear Medicine.

[36]  Masato Nakamura,et al.  FDG-PET and diffusion-weighted MR imaging appearance in retroperitoneal Castleman's disease: a case report. , 2008, Clinical imaging.

[37]  A. Dispenzieri.  Castleman disease. , 2008, Cancer treatment and research.

[38]  K. Hongo,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[39]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[40]  R. Reznek,et al.  CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas) , 2004, European Radiology.

[41]  J. Strauchen.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[42]  W. Mann,et al.  [Fluorine-18]Fluorodeoxyglucose Positron Emission Tomography, DNA Ploidy and Growth Fraction in Squamous-Cell Carcinomas of the Head and Neck , 2001, ORL.

[43]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[44]  J. Paul,et al.  Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus , 1999, European Radiology.

[45]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[46]  K. Inada,et al.  Localized Mediastinal Lymph‐Node Hyperplasia Resembling Thymoma , 1958, Annals of surgery.

[47]  B. Castleman,et al.  Localized mediastinal lymph‐node hyperplasia resembling thymoma , 1956, Cancer.